Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Here, we review the scope of tau and TDP-43 phosphorylation in neurodegenerative disease and discuss recent work demonstrating the kinases TTBK1 and TTBK2 phosphorylate both tau and TDP-43, promoting neurodegeneration.
|
31034749 |
2019 |
Tauopathies
|
0.010 |
Biomarker
|
group |
BEFREE |
Both TTBK1 and TTBK2 were initially identified as tau kinases and TTBK1 has been shown to phosphorylate tau epitopes commonly observed in Alzheimer's disease and other tauopathies.
|
29409526 |
2018 |
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
TTBK2 circular RNA promotes glioma malignancy by regulating miR-217/HNF1β/Derlin-1 pathway.
|
28219405 |
2017 |
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Stable knockdown of circ-TTBK2 or overexpression of miR-217 glioma cell lines (U87 and U251) were established to explore the function of circ-TTBK2 and miR-217 in glioma cells.
|
28219405 |
2017 |
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Remarkably, circ-TTBK2 knockdown combined with miR-217 overexpression led to tumor regression in vivo.
|
28219405 |
2017 |
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
TTBK2 circular RNA promotes glioma malignancy by regulating miR-217/HNF1β/Derlin-1 pathway.
|
28219405 |
2017 |
Amyotrophic Lateral Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, protein levels of TTBK1 and TTBK2 are increased in frontal cortex of FTLD-TDP patients, and TTBK1 and TTBK2 co-localize with TDP-43 inclusions in ALS spinal cord.
|
25473830 |
2014 |
Frontotemporal dementia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, protein levels of TTBK1 and TTBK2 are increased in frontal cortex of FTLD-TDP patients, and TTBK1 and TTBK2 co-localize with TDP-43 inclusions in ALS spinal cord.
|
25473830 |
2014 |
Renal Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines.
|
22020623 |
2012 |
Renal carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines.
|
22020623 |
2012 |
Movement Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Mutations that truncate the C-terminal non-catalytic moiety of TTBK2 (tau tubulin kinase 2) cause the inherited, autosomal dominant, SCA11 (spinocerebellar ataxia type 11) movement disorder.
|
21548880 |
2011 |
Ataxia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We provided the evidence that SCA11 is a rare form of ataxia in China.
|
19768375 |
2010 |
Cerebellar Ataxia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We provided the evidence that SCA11 is a rare form of ataxia in China.
|
19768375 |
2010 |
Cardiac Arrest
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Researchers have recently found that SCA type 11 (SCA11) is associated with mutations in the TTBK2 gene.
|
19768375 |
2010 |
Spinocerebellar Degeneration
|
0.010 |
Biomarker
|
group |
BEFREE |
These data suggest that TTBK2 is important in the tau cascade and in spinocerebellar degeneration.
|
18037885 |
2007 |
Spinocerebellar Degeneration
|
0.010 |
Biomarker
|
group |
LHGDN |
These data suggest that TTBK2 is important in the tau cascade and in spinocerebellar degeneration.
|
18037885 |
2007 |
Spinocerebellar tract degeneration
|
0.010 |
Biomarker
|
disease |
BEFREE |
These data suggest that TTBK2 is important in the tau cascade and in spinocerebellar degeneration.
|
18037885 |
2007 |
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
We reveal that many hub genes and TFs including ttbk-2, daf-16, and unc-49 have human and mouse orthologues that are directly or potentially associated with AD and neural development.
|
31291334 |
2019 |
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Both TTBK1 and TTBK2 were initially identified as tau kinases and TTBK1 has been shown to phosphorylate tau epitopes commonly observed in Alzheimer's disease and other tauopathies.
|
29409526 |
2018 |
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Triglycerides measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A large electronic-health-record-based genome-wide study of serum lipids.
|
29507422 |
2018 |
High density lipoprotein measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A large electronic-health-record-based genome-wide study of serum lipids.
|
29507422 |
2018 |
Deglutition Disorders
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Dysarthria
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Dystonia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|